Processa Pharmaceuticals (NASDAQ:PCSA) Receives "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Processa Pharmaceuticals (NASDAQ:PCSA – Free Report) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock. HC Wainwright also issued estimates for Processa Pharmaceuticals’ Q2 2024 earnings at ($0.98) EPS, Q3 2024 earnings at ($1.02) EPS, FY2024 […]

Related Keywords

, Processa Pharmaceuticals Company Profile , Processa Pharmaceuticals Inc , News Ratings For Processa Pharmaceuticals Daily , Processa Pharmaceuticals Stock Down , Institutional Investors Weigh In On Processa Pharmaceuticals , Processa Pharmaceuticals , Nasdaq , Free Report , Pharmaceuticals Stock Down , Get Free Report , Processa Pharmaceuticals Daily ,